医学
临床试验
内科学
物理疗法
临床研究阶段
不利影响
外科
梅德林
类风湿性关节炎
随机对照试验
安全概况
重症监护医学
相(物质)
作者
Tian Liu,Chun Li,Wenjie Zheng,Jianping Tang,Dan Chen,Yun Peng,Songlou Yin,Dongmei Zhou,Zhuoli Zhang,Cibo Huang,Lie Dai,Xiuning Wei,Lin Jin,Ye Yu,Lijun Wu,Zhenchun Zhang,Shengyun Liu,Xiaomei Li,Lindi Jiang,Jian Wu
标识
DOI:10.1016/j.ard.2026.01.014
摘要
OBJECTIVES: This study aimed to evaluate the efficacy and safety of mufemilast, a novel small-molecule selective phosphodiesterase 4 (PDE4) inhibitor, in patients with Behçet's syndrome (BS). METHODS: Patients diagnosed with BS according to the International Diagnostic (Classification) Criteria for Behçet's Disease 2013 and with active oral ulcers were eligible. Patients were randomly assigned to mufemilast (45 mg or 60 mg) or placebo, administered orally twice daily for 12 weeks. The primary endpoint was the area under the curve (AUC) for the number of oral ulcers from baseline to week 12. Safety was measured in all patients who received at least 1 dose of the study drug (ClinicalTrials: NCT04609397). RESULTS: for oral ulcers between the 45 mg and 60 mg groups and the placebo was -104.8 (95% CI, -156.3 to -53.2; P < .001) and -142.5 (95% CI, -192.4 to -92.7; P < .001), respectively. The visual analogue pain scores and time to ulcer-free remission were significantly improved with mufemilast (P < .001). PDE4-related side effects were transient and resolved spontaneously, and discontinuation rates were low (7% for 45 mg, 7% for 60 mg, and 3% for placebo). No serious adverse events were reported related to the drug. CONCLUSIONS: Among patients with oral ulcers associated with BS, mufemilast significantly reduced the number of oral ulcers, improved pain scores, and induced significantly more ulcer-free remissions compared with placebo, with an acceptable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI